This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Nab-Rapamycin
Description: ABI-009 is a an albumin-bound mammalian target of rapamycin (mTOR) kinase inhibitor. The mTOR is a cell-signaling protein that regulates the response of tumor cells to nutrients and growth factors, as well as controls tumor blood supply through effects on vascular endothelial growth factor (VEGF). The mTOR pathway is thought to be overactivated in numerous tumors and plays a critical role in cell survival and resistance to chemotherapy. Inhibition of mTOR activity prevents the signaling to important pathways that control cell growth and lead to a lowering of VEGF levels, thus decreasing the ability of tumors to gain their own blood supply (angiogenesis).
Celgene and Abraxis
In June 2010, Celgene and Abraxis jointly announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Abraxis BioScience. Under the terms of the merger agreement, each share of Abraxis BioScience common stock will be converted into the right to receive an upfront payment of $58.00 in cash and 0.2617 shares of Celgene common stock. The upfront payment values Abraxis BioScience at approximately $2.9 billion, net of cash. Each share will also receive one tradeable Contingent Value Right (CVR), which entitles its holder to receive payments for future regulatory milestones and commercial royalties. In October 2010, the acquisition was completed.
Celgene and AADi
Sometime in 2012 or 2013, Aadi, LLC, a start-up company, in-licensed ABI-009, a nab-rapmycin compound, from Celgene.
In May 2014, AADi announced the inlicensing of ABI-009 from Celgene. As part of the licensing agreement, AADi plans to develop...See full deal structure in Biomedtracker
Partners: Celgene Corporation
Pink Sheet Weekly Trademark Review Dec. 8, 2015
Additional information available to subscribers only: